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### Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy ![](fx1_lrg.gif) {#sec1.1.1}
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Treatment strategies are limited for patients with nonobstructive hypertrophic cardiomyopathy (nHCM). Cardiac transplantation may be the only option for those with severe, refractory symptoms. The primary objective of the phase II MAVERICK-HCM study was to assess the safety and tolerability of mavacamten, a first-in-class, small molecule inhibitor of cardiac myosin-adenosine triphosphatase, in symptomatic nHCM. Mavacamten was tolerated by most participants. Clinical parameters, including ejection fraction, will guide dosing. Exploratory analyses identified dose-dependent reduction in levels of N-terminal pro−B-type natriuretic peptide and cardiac troponin, which suggested potential benefit. This study provides groundwork for a future, larger-scale study to address unmet needs.
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### Lessons From MAVERICK-HCM: The Need for Less Speed {#sec1.2.1}
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### Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis ![](fx1_lrg.gif) {#sec1.3.1}
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The DAEDALUS (Difference in Antirestenotic Effectiveness of Drug-Eluting Stent and Drug-Coated Balloon Angioplasty for the Occurrence of Coronary In-Stent Restenosis) study was a pooled analysis of all 10 randomized clinical trials comparing drug-coated balloon (DCB) angioplasty with repeat stenting with drug-eluting stent (DES) for the treatment of in-stent restenosis (ISR). The present analysis shows that at 3-year follow-up the 2 strategies are similarly effective and safe for the treatment of bare-metal stent (BMS)--ISR, whereas DCB angioplasty is less effective but apparently similarly safe compared with repeat DES implantation for the treatment DES-ISR. DES-ISR is associated with higher rates of treatment failure and similar safety compared with bare-metal stent--ISR.
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### Differential Effects of Drug-Coated Balloon Angioplasty for In-Stent Restenosis {#sec1.4.1}
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### Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia ![](fx1_lrg.gif) {#sec1.5.1}
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Levels of atherogenic lipoprotein(a) are increased in patients with familial hypercholesterolemia (FH), but the reasons for this are unclear. Here, the authors compare the levels of lipoprotein(a) in individuals: 1) ascertained for clinical FH; and 2) genetically ascertained from the general population. The results suggest that FH does not cause elevated lipoprotein(a), but that elevated lipoprotein(a) increases the likelihood that an individual with FH will be clinically recognized. These findings stress the importance of testing lipoprotein(a) to differentiate FH from elevated lipoprotein(a) or the combination of both to inform accurate diagnosis, risk stratification, and treatment strategies.
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### Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them {#sec1.6.1}
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### A Population-Based Registry of Patients With Inherited Cardiac Conditions and Resuscitated Cardiac Arrest ![](fx1_lrg.gif) {#sec1.7.1}
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An algorithmic approach to the investigation of resuscitated sudden cardiac arrest (RSCA) after congenital and acquired disease was excluded identified one-half with a cardiac inherited disease (CID). The most common CID to be identified was long QT syndrome (42%). However, for subjects \>40 years of age, hypertrophic cardiomyopathy was the most common (33%). In the national Cardiac Inherited Diseases Registry New Zealand, the CID most likely to present with RSCA was catecholaminergic polymorphic ventricular tachycardia (53%), and the least likely was hypertrophic cardiomyopathy (8%); in between was Brugada syndrome (33%), arrhythmogenic right ventricular cardiomyopathy (25%), long QT syndrome (20%), and dilated cardiomyopathy (9%). Only 30% of RSCA due to CID occurred during exercise.
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### What Is the Risk of Sudden Cardiac Arrest in Inherited Cardiac Conditions? {#sec1.8.1}
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### Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients ![](fx1_lrg.gif) {#sec1.9.1}
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The Academic Research Consortium (ARC) defines patients as having a high bleeding risk (HBR) if they fulfill at least 1 major or 2 minor ARC-HBR criteria. The present investigation validates this recently introduced definition in a contemporary cohort of 9,623 patients who underwent coronary stenting; 44.4% of these patients qualified as HBR. The rate of bleeding complications at 1 year was about 3 times higher in HBR patients compared with non-HBR patients (9.1% vs. 3.2%; p \< 0.001). There was a stepwise increase in bleeding risk reflecting the increasing prevalence of multiple ARC-HBR criteria. HBR patients also experienced significantly higher rates of myocardial infarction and all-cause mortality.
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### Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: *JACC* State-of-the-Art Review ![](fx1_lrg.gif)![](fx3_lrg.gif)![](fx4_lrg.gif) {#sec2.1.1}
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Although conventionally viewed as distinct disease processes, cardiovascular disease (CVD) and cancer share common pathophysiological mechanisms for disease development and progression. Importantly, blood- and tissue-based biomarkers may provide insight into the mechanistic overlap underlying these 3 diseases. Cellular stress, inflammation, cellular proliferation, neurohormonal stress, angiogenesis, and genomic instability each represent shared mechanisms for which candidate biomarkers may improve our understanding of the fundamental commonalities, risk, and prognosis of CVD and cancer.
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### American College of Cardiology: Leading Through Change, Moving the Profession Forward {#sec3.1.1}
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### African-American COVID-19 Mortality: A Sentinel Event {#sec3.1.1t}
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### Treatment of AF in American Indians and Alaska Natives: Insights From the NCDR PINNACLE-AF Registry {#sec3.1.1y}
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### Impact of Beta-Blockers on Birth Weight in a High-Risk Cohort of Pregnant Women With CVD {#sec3.1.2}
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